FDA Expands Nevisense Use to More Healthcare Professionals in the U.S.

SciBase has received FDA approval to extend the labeling of its AI-based skin diagnostic device Nevisense, announced in a press release. The updated labeling now allows physician assistants and medical assistants in dermatology clinics to perform the Nevisense procedure, provided a dermatologist initiates the test.

Previously, only dermatologists were authorized to perform Nevisense measurements. The change aims to make the technology easier to integrate into clinical workflows and expand its accessibility to patients. Nevisense combines electrical impedance spectroscopy (EIS) with AI to assist in the detection of skin disorders, including melanoma.

According to SciBase, the broader labeling will enable more efficient use of Nevisense in dermatology practices and labs, supporting its adoption across the U.S. market.